oligodendroglioma : Related Words Words similar in meaning to oligodendroglioma
- oligodendrocyte«
- oligodendrogliomas«
- oligoastrocytoma«
- tumor«
- glioma«
- deletion«
- glial«
- anaplastic oligodendrogliomas«
- temozolomide«
- patient«
- codeletion«
- median survival«
- grade«
- radiation«
- chemotherapy«
- genetic signature«
- who guideline«
- diagnosis«
- grade oligodendrogliomas«
- classic oligodendrogliomas«
- prognostic relevance«
- median progression free survival«
- glial neoplasm«
- survival«
- cycle«
- tp53 mutation«
- virtual karyotyping«
- dosing schedule«
- neuropathologists«
- grade glioma«
- month«
- glioblastoma«
- recent study«
- study«
- progression«
- low grade«
- oncologist«
- treatment«
- radiation therapy«
- necrosis«
- type«
- brain«
- prognosis«
- standard glioblastoma«
- standard dosing schedule«
- proneural glioma«
- potential morbidity«
- pola.org/app/download/24869531/la+lettre_renop_5.pdf«
- perineuronal satellitosis«
- pcv treatment«
- pcv therapy«
- pcv chemotherapy«
- oxford neurosymposium study«
- oncogenic lesion«
- oligodendroliomas«
- oligodendroglioma component«
- normal resident oligodendroglia«
- normal brain parenchyma«
- njds gene mutation«
- neurooncologists«
- neoplastic oligodendrocyte«
- monotonous round cell appearance«
- monotonous population«
- microscopic appearance«
- malignant oligodendroglioma«
- lower daily dos«
- inevitable interobserver variability«
- histopathological grading«
- histopathologic grading«
- healthy brain structure«
- grey matter structure«
- grade iv oligodendrogliomas«
- glial tumour«
- genotoxic therapy«
- distinction controversial«
- differentiation obsolete«
- common structural deformity«
- common chemotherapeutic drug«
- common astrocytomas«
- common astrocytoma«
- combined tumor«
- classic radiology imaging«
- chromosomal arm 1p«
- astrocytoma differentiation«
- anaplastic oligodendroglioma patient«
- >123 month«
- short term«
- vague nodule«
- unusual diagnosis«
- temozolomide therapy«
- oligodendroglial differentiation«
- most larger cancer treatment center«
- mixed oligoastrocytomas«
- low mitotic activity«
- indolent nature«
- heterozygosity status«
- heter/homogeneity«
- grade glioma patient«
- glioneuronal tumor«
- epidermal growth factor receptor amplification«
- egfr amplification«
- continuous daily dosing«
- adjacent brain structure«
- typical life expectancy«
- temozolomide treatment«
- overwhelming feature«
- key locus«
- increased intracranial pressure«
- primary brain«
- histological grading«
- glial precursor cell«
- dysembryoplastic neuroepithelial tumor«
- classic variant«
- central neurocytoma«
- proneural gene«
- hypercellularity«
- biopsy examination«
- anaplastic oligodendroglioma«
- vascular proliferation«
- compact nucleus«
- classical variant«
- asco annual meeting«
- allelic loss«
- chemosensitivity«
- molecular genetics«
- histopathologic examination«
- improved prognosis«
- % correlation«
- radiographic appearance«
- glial tumor«
- recurrent tumor«
- grade lesion«
- eosinophilic cytoplasm«
- central nervous system tumor«
- ccnu«
- pilocytic astrocytoma«
- round nucleus«
- pial surface«
- aggressive chemotherapy«
- tumor initiation«
- primary brain tumor«
- histologic appearance«
- diagnostic utility«
- round cell«
- motor weakness«
- cell due«
- term«
- week«
- pleomorphism«
- grade iii.«
- chromosomal deletion«
- prolonged survival«
- ependymoma«
- median survival time«
- grade ii«
- tumor mass«
- procarbazine«
- previous diagnosis«
- p53 gene«
- daily dosing«
- brain swelling«
- stereotactic surgery«
- pathology report«
- brain biopsy«
- subjective criterion«
- westergaard«
- loss«
- adjuvant chemotherapy«
- final diagnosis«
- watchful waiting«
- % survival rate«
- historic data«
- chemotherapeutic drug«
- seizure activity«
- median time«
- oligo«
- visual loss«
- pituitary adenoma«
- duration«
- day cycle«
- molecular diagnostics«
- neurological deficit«
- surgery«
- treatment decision«
- symptomatic treatment«
- aggressive treatment«
- vincristine«
- glioblastoma multiforme«
- chemotherapy regimen«
- chicken wire«
- current treatment«
- surgical excision«
- brain lesion«
- free survival«
- line therapy«
- heterozygosity«
- dosing«
- retrospective study«
- cognitive decline«
- egfr«
- loh«
- entire genome«
- neuropathology«
- fried egg«
- vasculature«
- clinical data«
- classically«
- ultimate responsibility«
- definitive diagnosis«
- poor prognosis«
- greek root«
- drug«
- researcher«
- lower amount«
- gene product«
- term survival«
- anticonvulsant«
- meaning«
- term study«
- strong correlation«
- promising result«
- radiotherapy«
- frontal lobe«
- capillary«
- translocation«
- irradiation«
- common symptom«
- status«
- significant advantage«
- neurosurgeon«
- tomography«
- striking feature«
- treatment option«
- category«
- kevin smith«
- symptoms«
- histology«
- assay«
- figure«
- etiology«
- magnetic resonance imaging«
- result«
- significant proportion«
- neurosurgery«
- cortex«
- schema«
- consecutive day«
- brain tumor«
- pathologist«
- recurrence«
- mri«
- average age«
- steroid«
- scan«
- locus«
- effect«
- mediator«
- significant difference«
- neuron«
- headache«
- world health organization«
- subgroup«
- appearance«
- efficacy«
- location«
- mutation«
- midwest«
- monitoring«
- sensitivity«
- seizure«
- time«
- consultation«
- anatomy«
- onset«
- guideline«
- appreciation«
- 1p/19q loss«
- 1p/19q deletion«
- 28-day cycle«
- 21-day dosing«
- 1p/19q locus«
- 1p loss«
- 19q deletion«
- 4-week«